JHS Svendgaard Laboratories Limited (IN:JHS)
:JHS
Want to see IN:JHS full AI Analyst Report?
JHS Stock Chart & Stats
₹9.34
₹0.02(0.10%)
At close: 4:00 PM EST
₹9.34
₹0.02(0.10%)
Day’s Range― - ―
52-Week Range₹6.15 - ₹14.04
Previous CloseN/A
Volume57.31K
Average Volume (3M)16.78K
Market Cap
₹733.63M
Enterprise Value₹746.79M
Total Cash (Recent Filing)₹200.11M
Total Debt (Recent Filing)₹105.87M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding85,603,966
10 Day Avg. Volume16,348
30 Day Avg. Volume16,781
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)0.33
Price to Sales (P/S)0.56
P/FCF Ratio-3.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetLow leverage and a stable equity base materially reduce solvency and refinancing risk over the medium term. This financial flexibility supports continued operations, selective capex or working-capital needs and gives management time to execute a turnaround without immediate pressure to deleverage.
Diversified Revenue Streams (branded + Contract Manufacturing)A dual model—own branded sales plus third-party contract manufacturing—provides structural revenue diversification and more stable factory utilization. Durable B2B contracts can smooth demand cycles and create recurring manufacturing income while branded growth adds upside to margins.
Revenue Rebound And EBITDA Recovery In FY2026An FY2026 revenue rebound with EBITDA returning to positive indicates improving top-line traction and capacity to cover fixed costs. If sustained, higher volumes combined with cost control can support a durable path to operating profitability and improved cash conversion.
Bears Say
Ongoing Losses And Negative MarginsPersistent negative net margins mean the firm has not yet converted revenue into shareholder returns, weighing on return metrics and reinvestment capability. Continued losses erode equity over time and limit management's ability to fund growth internally without altering cost structure or pricing.
Weak, Inconsistent Cash GenerationRepeated negative operating and free cash flow across years signals structurally weak cash conversion and execution risk. Sustained cash burn increases reliance on working-capital swings or external financing, constraining capital allocation and exposing the business to funding stress in downturns.
Gross Margin Compression / Pricing PressureSharp gross margin compression suggests structural margin headwinds from cost inflation or competitive pricing. Even with higher sales, squeezed gross margins reduce operating leverage, making it harder to achieve sustainable profitability and limiting cash generation from increased volumes.
JHS Svendgaard Laboratories Limited News
JHS FAQ
What was JHS Svendgaard Laboratories Limited’s price range in the past 12 months?
JHS Svendgaard Laboratories Limited lowest stock price was ₹6.15 and its highest was ₹14.04 in the past 12 months.
What is JHS Svendgaard Laboratories Limited’s market cap?
JHS Svendgaard Laboratories Limited’s market cap is ₹733.63M.
When is JHS Svendgaard Laboratories Limited’s upcoming earnings report date?
JHS Svendgaard Laboratories Limited’s upcoming earnings report date is Aug 17, 2026 which is in 72 days.
How were JHS Svendgaard Laboratories Limited’s earnings last quarter?
JHS Svendgaard Laboratories Limited released its earnings results on May 26, 2026. The company reported -₹0.42 earnings per share for the quarter, missing the consensus estimate of N/A by -₹0.42.
Is JHS Svendgaard Laboratories Limited overvalued?
According to Wall Street analysts JHS Svendgaard Laboratories Limited’s price is currently Overvalued.
Does JHS Svendgaard Laboratories Limited pay dividends?
JHS Svendgaard Laboratories Limited pays a Annually dividend of ₹0.75 which represents an annual dividend yield of N/A. See more information on JHS Svendgaard Laboratories Limited dividends here
What is JHS Svendgaard Laboratories Limited’s EPS estimate?
JHS Svendgaard Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JHS Svendgaard Laboratories Limited have?
JHS Svendgaard Laboratories Limited has 85,603,966 shares outstanding.
What happened to JHS Svendgaard Laboratories Limited’s price movement after its last earnings report?
JHS Svendgaard Laboratories Limited reported an EPS of -₹0.42 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of JHS Svendgaard Laboratories Limited?
Currently, no hedge funds are holding shares in IN:JHS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JHS Svendgaard Laboratories Limited
JHS Svendgaard Laboratories Limited, together with its subsidiaries, manufactures and sells a range of oral and dental products for adults and kids in India. The company offers oral care products, such as toothbrushes, toothpastes, mouthwash products, hand sanitizers, laundry detergents, room fresheners, and denture products under the Dr. Gold and Aquawhite brands. It also provides contract manufacturing services for oral care products of other brands; and operates retail stores at airports. The company also exports its products. JHS Svendgaard Laboratories Limited was founded in 1996 and is based in New Delhi, India.
Technical Analysis
Colgate-Palmolive (India) Limited
―
Dabur India Limited
―
Emami Limited
―
Godrej Consumer Products Limited
―
Honasa Consumer Limited
―